Market open
Cognition Therapeutics/$CGTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cognition Therapeutics
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Ticker
$CGTX
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
27
ISIN
US19243B1026
Website
CGTX Metrics
BasicAdvanced
$20M
-
-$0.72
-
-
Price and volume
Market cap
$20M
52-week high
$0.50
52-week low
$0.28
Average daily volume
846K
Financial strength
Current ratio
2.088
Quick ratio
1.937
Long term debt to equity
2.282
Total debt to equity
3.863
Interest coverage (TTM)
-2,681.95%
Management effectiveness
Return on assets (TTM)
-107.53%
Return on equity (TTM)
-161.93%
Valuation
Price to book
1.62
Price to tangible book (TTM)
1.62
Price to free cash flow (TTM)
-0.483
Growth
Earnings per share change (TTM)
-21.97%
3-year earnings per share growth (CAGR)
-26.27%
CGTX News
AllArticlesVideos
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
GlobeNewsWire·5 days ago
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes
GlobeNewsWire·1 month ago
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cognition Therapeutics stock?
Cognition Therapeutics (CGTX) has a market cap of $20M as of May 14, 2025.
What is the P/E ratio for Cognition Therapeutics stock?
The price to earnings (P/E) ratio for Cognition Therapeutics (CGTX) stock is 0 as of May 14, 2025.
Does Cognition Therapeutics stock pay dividends?
No, Cognition Therapeutics (CGTX) stock does not pay dividends to its shareholders as of May 14, 2025.
When is the next Cognition Therapeutics dividend payment date?
Cognition Therapeutics (CGTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Cognition Therapeutics?
Cognition Therapeutics (CGTX) does not currently have a Beta indicator.